All Healthcare articles – Page 3
-
Video2022: An even brighter future for disruptive tech
The pandemic has sped up a transformation in technology that would otherwise have taken years, triggering a sea change in how we work, buy and communicate. Advances in, for example, cloud computing, the internet of things and artificial intelligence are affecting industries as diverse as financial services, healthcare and consumer goods and creating opportunities for investors.
-
VideoSynthetic Biology: Investing in the Science of Sustainability
If the technology for making diabetes medicine hadn’t changed since the 1930s, today we’d need an area larger than the surface of the earth for raising pigs, harvesting insulin from their pancreases to help hundreds of millions of diabetics around the world.
-
White papersOmicron Soon to Be the Dominant Variant in the U.S…Is This Strain the Way Out of the Pandemic?
We thought it might be helpful to frame our latest thinking on the SARS-CoV2 Omicron variant now that we have seen more data out of South Africa on the evolution of this viral variant.
-
White papersHow investing in biotech can help achieve the SDGs
From pioneering therapies to renewable food sources, biotechnology has the potential to address many of humanity’s greatest challenges, as aligned to the United Nations’ Sustainable Development Goals (SDGs).
-
White papersOmicron: The Reason to Seriously Consider Getting a Third COVID-19 Vaccine Shot
Pfizer data suggests a third dose of Comirnaty (COVID-19 vaccine) appeared to increase neutralizing antibodies 25-fold against the Omicron variant, a level suggesting protective immunity against severe COVID-19.
-
White papersGeopolitics of the vaccine: variance risks
Covid-19 vaccines have been rolled out for a year now. Despite official commitments to provide access to effective jabs to all countries, production constraints and national priorities have resulted in uneven distribution, with some countries close to 100% vaccination rates while others are still below 5%.
-
Research ReportReal Estate Convictions - November 2021
In a world dominated by uncertainty, the recovery in the global economy continues. With the on-going vaccination of the general population and booster campaigns remaining a strategic priority, to avoid the introduction of new health restrictions that would deteriorate growth in late 2021 and early 2022, the deterioration of short-term prospects has come from China.
-
White papersNovo Nordisk Throws Its Weight Behind Patients With Obesity And Diabetes
The world’s obesity and sugar-high problems have healthcare budgets bursting at the seams.
-
White papersBattling the superbugs
Antimicrobial resistance (AMR) is growing, although the risk too often goes unmanaged or ignored. Yet the ramifications for public health are huge.
-
Research ReportClimate crisis in focus in EOS’s Q3 Public Engagement Report
With scientists calling for urgent action on climate change following another year of devastating wildfires and floods, November’s COP26 summit is considered critical.
-
-
White papers5 trends driving the future of biotech
I am often asked about my outlook for biotechnology in light of how rapidly vaccines were developed for COVID-19. I would say this may be a sign of things to come for the industry. I’ve been seeing a renaissance that’s led to an explosion of novel drug targets in recent years.
-
White papersCOVID-19 Strained Participant Financial Wellness: Can Employers Help Them Recover?
With COVID-19 still a top employer concern, protecting workers’ health and well-being naturally comes first. But the pandemic’s impact isn’t limited to only physical and mental health: financial wellness is also ailing. The crisis has exacerbated the problem, but it’s not exactly a sudden occurrence.
-
White papersVaccinations and Boosters; the U.S. Food and Drug Administration (FDA) Makes a Strong Statement
We thought it would be helpful to opine on conflicting data with respect to the potential protection afforded by natural immunity versus that derived from vaccination, as well as the recent FDA decision to recommend COVID-19 boosters for those over 65 years of age and/or at high risk of severe COVID-19.
-
White papersBrace Yourself for the Pivot from COVID to Climate
The pandemic forced governments to plow resources into consumption, but climate challenges will require lots (and lots) of investment.
-
Research ReportImpact Opportunities - Impact Annual Report, 2020
Covid-19 has resulted in a paradigm shift: it has thrown into sharp focus the need for resilient healthcare systems and supply chains, while also highlighting the climate change crisis and workers’ rights issues.
-
White papersHow Big Data Casts New Light on Reopening Stocks
Our recent work on the COVID-19 Delta variant not only reminds us that data science can give us insights into the pandemic, but also about the ways alternative data need to be marshaled to provide actionable information for our investment views.
-
White papersThe ABCs of the Delta Variant: Anxiety, Boosters and Communication
In an effort to bring timely insights during these uncertain times, we are pleased to share an update from Terri Towers, PhD, Senior Healthcare Analyst, who shares her views on the COVID-19 (“Coronavirus”) pandemic.
-
White papersTrading the Vaccine Curve
Today, as many economies approach the final stages of their COVID-19 vaccination programs, unlocking activity hard hit by lockdowns, their experience provides an important guide for investors as to how other countries, further behind with their vaccination programs, may perform in coming quarters.
-
White papersEngaging with the animal health sector to prevent the next public health crisis
Dr Emma Berntman sets outs the gravity of AMR risk, why a multistakeholder approach is crucial and the findings from the FAIRR initiative’s latest report we have contributed to.
